TD Asset Management
PCRX icon

TD Asset Management’s Pacira BioSciences PCRX Stock Holding History

TD Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,300
Closed -$658K – 1380
2018
Q4 		$658K Sell
15,300
-7,200
-32% -$336K ﹤0.01% 1162
2018
Q3 		$1.11M Sell
22,500
-4,700
-17% -$203K ﹤0.01% 1134
2018
Q2 		$872K Sell
27,200
-1,900
-7% -$65.6K ﹤0.01% 1163
2018
Q1 		$906K Buy
29,100
+1,800
+7% +$64.1K ﹤0.01% 1084
2017
Q4 		$1.25M Buy
27,300
+1,500
+6% +$59.4K ﹤0.01% 998
2017
Q3 		$969K Sell
25,800
-4,763
-16% -$192K ﹤0.01% 1040
2017
Q2 		$1.46M Sell
30,563
-5,700
-16% -$264K ﹤0.01% 952
2017
Q1 		$1.65M Sell
36,263
-5,800
-14% -$251K ﹤0.01% 929
2016
Q4 		$1.36M Sell
42,063
-20,137
-32% -$672K ﹤0.01% 948
2016
Q3 		$2.13M Sell
62,200
-14,000
-18% -$548K ﹤0.01% 867
2016
Q2 		$2.57M Buy
76,200
+4,200
+6% +$206K ﹤0.01% 814
2016
Q1 		$3.81M Sell
72,000
-2,700
-4% -$158K 0.01% 732
2015
Q4 		$5.74M Buy
74,700
+1,300
+2% +$73.6K 0.01% 612
2015
Q3 		$3.02M Buy
73,400
+2,100
+3% +$129K 0.01% 750
2015
Q2 		$5.04M Sell
71,300
-9,100
-11% -$717K 0.01% 674
2015
Q1 		$7.14M Buy
80,400
+7,500
+10% +$761K 0.01% 575
2014
Q4 		$6.46M Sell
72,900
-12,700
-15% -$1.2M 0.01% 600
2014
Q3 		$8.3M Buy
85,600
+6,400
+8% +$623K 0.01% 513
2014
Q2 		$7.28M Sell
79,200
-2,100
-3% -$160K 0.01% 548
2014
Q1 		$5.69M Buy
81,300
+5,000
+7% +$340K 0.01% 612
2013
Q4 		$4.39M Sell
76,300
-1,600
-2% -$84.1K 0.01% 665
2013
Q3 		$3.75M Sell
77,900
-3,500
-4% -$128K 0.01% 680
2013
Q2 		$2.36M Buy
+81,400
New +$2.35M 0.01% 738

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TD Asset Management's PCRX Position: Q1 2019 in Review

TD Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2019, closing a stake of 15,300 shares — an estimated $658K sold.

TD Asset Management first reported a position in PCRX in Q2 2013 and held it in 23 quarters. The position peaked at $8.3M in Q3 2014. 210 funds tracked by Wall St. Rank hold PCRX as of Q1 2019.

  • TD Asset Management reported no remaining Pacira BioSciences position as of Q1 2019 after selling out during the quarter.
  • TD Asset Management sold 15,300 Pacira BioSciences shares in Q1 2019, an estimated $658K.
  • TD Asset Management first reported a position in Pacira BioSciences in Q2 2013 and held it in 23 quarters.
  • TD Asset Management's Pacira BioSciences position peaked at $8.3M in Q3 2014.
  • 210 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2019.

Based on TD Asset Management's 13F filing for Q1 2019, filed 8 May 2019.